Press Releases

Study from MSK and Epic Sciences Shows Only Nuclear-localized AR-V7 Is Predictive of Therapy Benefit for Patients with Metastatic Prostate Cancer

Investigators from Memorial Sloan Kettering Cancer Center (MSK) and Epic Sciences published findings in European Urology, that only nuclear localization of AR-V7 protein in circulating tumor cells (CTCs) from metastatic castration resistant prostate…

Liquid Biopsy Biomarker Identifies Patients with Improved Response to PARP Inhibition in Metastatic Castrate Resistant Prostate Cancer

Epic Sciences announced findings demonstrating a circulating tumor cell (CTC) biomarker can identify patients with metastatic castrate resistant prostate cancer (mCRPC) who are more likely to respond to treatment with a PARP inhibitor in combination with…

Epic Sciences Validates Single CTC Sequencing, Identifies Clonal Heterogeneity in Metastatic Cancer

Epic Sciences, in collaboration with pharma co-authors, published an analytic validation of their sequencing assay in single circulating tumor cells (CTC) and demonstrated clinical feasibility in metastatic prostate cancer patients (mCRPC). In addition…

Epic Sciences to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum

Epic Sciences, Inc. ("Epic"), a private biotech company that designs and develops predictive tests of therapy response in cancer, announced today that Murali K. Prahalad, Ph.D., chief executive officer, will present at the Canaccord Genuity Medical…

Epic Sciences to Contribute to Cancer Moonshot Blood Profiling Atlas

Epic Sciences in collaboration with other industry, academic and government partners will contribute to the Blood Profiling Atlas pilot of the Cancer Moonshot Initiative championed by Vice President Biden and the White House. The Blood Profiling Atlas…

Genomic Health and Epic Sciences Announce Strategic Collaboration to Deliver Novel AR-V7 Liquid Biopsy Test

Genomic Health, Inc. and Epic Sciences, Inc. announced an exclusive agreement to commercialize Epic Sciences’ novel AR-V7 liquid biopsy test in the United States through Genomic Health’s world-class commercial channel.

Epic Sciences Introduces Sensitive HRD Liquid Biopsy Test for PARP Inhibitor Clinical Trials

Epic Sciences unveiled a liquid biopsy test that more sensitively detects cancers susceptible to PARP inhibitors by targeting homologous recombination deficiency (HRD) in individual circulating tumor cells (CTCs).

Presence of AR-V7 in Circulating Tumor Cells Validated as Predictive Biomarker for Advanced Prostate Cancer Treatment by Memorial Sloan Kettering and Epic Sciences

New Publication: JAMA Oncology 2016. Presence of AR-V7 in Circulating Tumor Cells Validated as Predictive Biomarker for Advanced Prostate Cancer Treatment by Memorial Sloan Kettering and Epic Sciences

Epic Sciences to Present at Molecular Medicine Tri-Con 2016

Epic Sciences, Inc. , announced today that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the Molecular Medicine Tri-Con 2016, taking place at the Moscone Convention Center, San Francisco.

Avera Medical Group And Epic Sciences Collaborate on Cancer Precision Medicine Clinical Trials

SAN DIEGO, January 28, 2016 /PRNewswire/ -- Epic Sciences, Inc. and Avera Medical Group announced today a collaboration on feasibility studies to better understand the effectiveness of personalized cancer treatments as part of novel ovarian and breast…